University Hospital, Montpellier — Biomedical Watch V2

Traitements21programmes

Essais10liés

Publications7liées

SourceDBlocale

Traitements

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
AMIS — Serum Neurofilaments and GFAP in Atypical Multiple SclerosisIdiopathic inflammatory disorders of the central nervous system include various disorders of which multiple sclerosis is the most common. Besides multiple sclerosis, other distinct disorders including for example anti-AQP4 (aquaporine-4) and anti-MOG (Myelin oligodendrocyte glycoprotein) NMOSD (Neuromyelitis optica spectrum disorder) have been well characterized and are now known to be distinct from MS. some patient belonging to MS spectrum have recently being characterized but unusual MRI findings have mimicking inherited leukoencephalopathies and leukodystrophies. Whether these patients with atypical phenotype represent a separate disease distinct from MS or belong to MS spectrum is not clear. The objectives are to evaluate a series of 15 patients with atypical forms of MS using non-conventional MRI techniques and biological biomarkers (serum neurofilaments light chain) and to compare them with classical MS patients (15 relapsing remitting patients and 15 progressive patients) and 15 controls. the hypothesize is that these patients with atypical MS have a more severe neurodegenerative process.	SEP	Non applicable	Remyélinisation	France	À vérifier
ANEX — Amyotrophic Lateral Sclerosis Non-invasive Ventilation ExchangeDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé.	Sclérose latérale amyotrophique	Non applicable	À vérifier	France	À vérifier
Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab)Multiple sclerosis (MS), the main central nervous system autoimmune disorder, is the first cause of non-traumatic disability in young adults and has thus significant individual consequences with elevated public health cost. It commonly starts during the third and fourth decades. Over the last twenty years, several disease-modifying therapies with variable benefit/risk profiles have been introduced leading to dramatic changes in the prognosis of MS. First, several moderately effective therapies , with good safety profile, have allowed to decrease the frequency of relapses along with a possible, albeit limited, effect on medium- and long-term disability. More recently highly effective therapies (HET), with immunosuppressive properties, have dramatically reduced clinical and MRI disease activity and significantly improved patient's prognosis. Anti-CD20 therapies (B-cells depleting therapies, given either intravenous or subcutaneous), one of the main HET, have demonstrated higher efficacy than platform therapies in several phase 3 randomized clinical trials and their use within the very first years of the disease seems to be associated with improved long-term outcomes. Taking all of this into account, the investigators hypothesize that RRMS patients who experience a de-escalation from anti-CD20 therapies to platform therapies after 40 years will not experience disease activity accrual and disability worsening.	SEP	Phase 3	Immunomodulation	France	À vérifier
Blood testDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé.	Sclérose latérale amyotrophique	Non applicable	À vérifier	France	À vérifier
DIAGONALS — Serum Neurofilaments in the Diagnosis of Amyotrophic Lateral SclerosisDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé.	Sclérose latérale amyotrophique	À vérifier	Ralentissement de la progression + Traitement symptomatique		À vérifier
Influence of Sodium Intake on Left Ventricular-arterial CouplingThe objective of the present study is to asses the effectiveness of the aorta-ventricular coupling according to low and high sodium intake in 28 controled hypertensive patients.	Hypertension	NA	À vérifier	France	À vérifier
Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons)Multiple sclerosis (MS), the main central nervous system autoimmune disorder, is the first cause of non-traumatic disability in young adults and has thus significant individual consequences with elevated public health cost. It commonly starts during the third and fourth decades. Over the last twenty years, several disease-modifying therapies with variable benefit/risk profiles have been introduced leading to dramatic changes in the prognosis of MS. First, several moderately effective therapies , with good safety profile, have allowed to decrease the frequency of relapses along with a possible, albeit limited, effect on medium- and long-term disability. More recently highly effective therapies (HET), with immunosuppressive properties, have dramatically reduced clinical and MRI disease activity and significantly improved patient's prognosis. Anti-CD20 therapies (B-cells depleting therapies, given either intravenous or subcutaneous), one of the main HET, have demonstrated higher efficacy than platform therapies in several phase 3 randomized clinical trials and their use within the very first years of the disease seems to be associated with improved long-term outcomes. Taking all of this into account, the investigators hypothesize that RRMS patients who experience a de-escalation from anti-CD20 therapies to platform therapies after 40 years will not experience disease activity accrual and disability worsening.	SEP	Phase 3	Immunomodulation	France	À vérifier
SAMCO-MIG — Sensitivity to Acute Cerebral Ischemia in MigrainersSensitivity to Acute Middle cerebral or intracranial Carotid artery Occlusion in MIGrainers (SMCO-MIG) is a prospective multi-center study to determine if migraine induces a faster infarct growth as assessed by initial multimodal imaging.	Migraine	À vérifier	À vérifier	France	À vérifier
Small and Steatotic Hepatocellular CarcinomaPercutaneous thermoablation in an effective local curative treatment in patients with cirrhosis and HCC smaller than 3 cm in diameter (BCLC 0-A). Around 30% of HCC patients referred for percutaneous ablation were regarded as non-feasible because of a difficult-at risk location or undetectable nodules. We used percutaneous thermoablation to treat HCC on high risk locations (subcapsular or liver dome) with or without lipiodol marked (for undetectable HCC). No clinical study has been published so far to compare percutaneous thermoablation of HCC on liver dome CT guided with artificial pneumothorax and lipiodol marked, and percutaneous thermoablation of HCC guided by ultrasonography (non subcapsular, distent form diaphragm). This retrospective study evaluate the overall survival, the local tumor progression or distant liver progression after percutaneous ablation for HCC and determine prognostic factors.	Cancer	À vérifier	Ralentissement de la progression	France	À vérifier
Telangiectatic Palmoplantar Keratoderma in Systemic and Subacute Lupus ErythematosusPalmoplantar keratoderma (PPK) associated to livid telangiectatic erythema during systemic lupus erythematosus (SLE) and subacute cutaneous lupus erythematosus (SCLE) is a rare phenomenon seldom reported in literature. The investigators hypothesize that clinic-immunologic assessment and detailed investigation of cutaneous biopsy specimen of PPK and erythema of patients suffering from SLE and SCLE could lead to determine more precisely nosological settings of this injury. Report the different therapeutics with efficacy assessment could be helpful to highlight useful treatment for these patients.	Lupus	À vérifier	À vérifier	France	À vérifier
UNZUELUZON ALS — Developing a Comprehensive Biomarker Panel for Monitoring Progression and Early Detection in ALS PatientsDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé.	Sclérose latérale amyotrophique	À vérifier	Ralentissement de la progression	France, Spain	À vérifier
Influence of Sodium Intake on Left Ventricular-arterial CouplingThe objective of the present study is to asses the effectiveness of the aorta-ventricular coupling according to low and high sodium intake in 28 controled hypertensive patients.	Hypertension	NA	À vérifier	France	À vérifier
Telangiectatic Palmoplantar Keratoderma in Systemic and Subacute Lupus ErythematosusPalmoplantar keratoderma (PPK) associated to livid telangiectatic erythema during systemic lupus erythematosus (SLE) and subacute cutaneous lupus erythematosus (SCLE) is a rare phenomenon seldom reported in literature. The investigators hypothesize that clinic-immunologic assessment and detailed investigation of cutaneous biopsy specimen of PPK and erythema of patients suffering from SLE and SCLE could lead to determine more precisely nosological settings of this injury. Report the different therapeutics with efficacy assessment could be helpful to highlight useful treatment for these patients.	Lupus	À vérifier	À vérifier	France	À vérifier
Small and Steatotic Hepatocellular CarcinomaPercutaneous thermoablation in an effective local curative treatment in patients with cirrhosis and HCC smaller than 3 cm in diameter (BCLC 0-A). Around 30% of HCC patients referred for percutaneous ablation were regarded as non-feasible because of a difficult-at risk location or undetectable nodules. We used percutaneous thermoablation to treat HCC on high risk locations (subcapsular or liver dome) with or without lipiodol marked (for undetectable HCC). No clinical study has been published so far to compare percutaneous thermoablation of HCC on liver dome CT guided with artificial pneumothorax and lipiodol marked, and percutaneous thermoablation of HCC guided by ultrasonography (non subcapsular, distent form diaphragm). This retrospective study evaluate the overall survival, the local tumor progression or distant liver progression after percutaneous ablation for HCC and determine prognostic factors.	Cancer	À vérifier	Ralentissement de la progression	France	À vérifier
UNZUELUZON ALS — Developing a Comprehensive Biomarker Panel for Monitoring Progression and Early Detection in ALS PatientsDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé.	Sclérose latérale amyotrophique	À vérifier	Ralentissement de la progression	France, Spain	À vérifier
DIAGONALS — Serum Neurofilaments in the Diagnosis of Amyotrophic Lateral SclerosisDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé.	Sclérose latérale amyotrophique	À vérifier	Ralentissement de la progression + Traitement symptomatique		À vérifier
SAMCO-MIG — Sensitivity to Acute Cerebral Ischemia in MigrainersSensitivity to Acute Middle cerebral or intracranial Carotid artery Occlusion in MIGrainers (SMCO-MIG) is a prospective multi-center study to determine if migraine induces a faster infarct growth as assessed by initial multimodal imaging.	Migraine	À vérifier	À vérifier	France	À vérifier
ANEX — Amyotrophic Lateral Sclerosis Non-invasive Ventilation ExchangeDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé.	Sclérose latérale amyotrophique	Non applicable	À vérifier	France	À vérifier
Blood testDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé.	Sclérose latérale amyotrophique	Non applicable	À vérifier	France	À vérifier
AMIS — Serum Neurofilaments and GFAP in Atypical Multiple SclerosisIdiopathic inflammatory disorders of the central nervous system include various disorders of which multiple sclerosis is the most common. Besides multiple sclerosis, other distinct disorders including for example anti-AQP4 (aquaporine-4) and anti-MOG (Myelin oligodendrocyte glycoprotein) NMOSD (Neuromyelitis optica spectrum disorder) have been well characterized and are now known to be distinct from MS. some patient belonging to MS spectrum have recently being characterized but unusual MRI findings have mimicking inherited leukoencephalopathies and leukodystrophies. Whether these patients with atypical phenotype represent a separate disease distinct from MS or belong to MS spectrum is not clear. The objectives are to evaluate a series of 15 patients with atypical forms of MS using non-conventional MRI techniques and biological biomarkers (serum neurofilaments light chain) and to compare them with classical MS patients (15 relapsing remitting patients and 15 progressive patients) and 15 controls. the hypothesize is that these patients with atypical MS have a more severe neurodegenerative process.	SEP	Non applicable	Remyélinisation	France	À vérifier
Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons)Multiple sclerosis (MS), the main central nervous system autoimmune disorder, is the first cause of non-traumatic disability in young adults and has thus significant individual consequences with elevated public health cost. It commonly starts during the third and fourth decades. Over the last twenty years, several disease-modifying therapies with variable benefit/risk profiles have been introduced leading to dramatic changes in the prognosis of MS. First, several moderately effective therapies , with good safety profile, have allowed to decrease the frequency of relapses along with a possible, albeit limited, effect on medium- and long-term disability. More recently highly effective therapies (HET), with immunosuppressive properties, have dramatically reduced clinical and MRI disease activity and significantly improved patient's prognosis. Anti-CD20 therapies (B-cells depleting therapies, given either intravenous or subcutaneous), one of the main HET, have demonstrated higher efficacy than platform therapies in several phase 3 randomized clinical trials and their use within the very first years of the disease seems to be associated with improved long-term outcomes. Taking all of this into account, the investigators hypothesize that RRMS patients who experience a de-escalation from anti-CD20 therapies to platform therapies after 40 years will not experience disease activity accrual and disability worsening.	SEP	Phase 3	Immunomodulation	France	À vérifier

Essais cliniques

Molécule	Indication / population	Phase	NCT	Titre	Statut
Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons)	SEP	Phase 3	NCT07189325	DESIRE MS — A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis	RECRUITING
AMIS — Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis	SEP	Non applicable	NCT04201470	AMIS — Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis	COMPLETED
Blood test	Sclérose latérale amyotrophique	Non applicable	NCT01823380	Influence of the Vitamin D Blood Levels on the Amyotrophic Lateral Sclerosis Phenotype	COMPLETED
ANEX — Amyotrophic Lateral Sclerosis Non-invasive Ventilation Exchange	Sclérose latérale amyotrophique	Non applicable	NCT05837507	ANEX — Amyotrophic Lateral Sclerosis Non-invasive Ventilation Exchange	TERMINATED
SAMCO-MIG — Sensitivity to Acute Cerebral Ischemia in Migrainers	Migraine	À vérifier	NCT03301441	SAMCO-MIG — Sensitivity to Acute Cerebral Ischemia in Migrainers	UNKNOWN
DIAGONALS — Serum Neurofilaments in the Diagnosis of Amyotrophic Lateral Sclerosis	Sclérose latérale amyotrophique	À vérifier	NCT07706270	DIAGONALS — Serum Neurofilaments in the Diagnosis of Amyotrophic Lateral Sclerosis	NOT_YET_RECRUITING
UNZUELUZON ALS — Developing a Comprehensive Biomarker Panel for Monitoring Progression and Early Detection in ALS Patients	Sclérose latérale amyotrophique	À vérifier	NCT07737977	UNZUELUZON ALS — Developing a Comprehensive Biomarker Panel for Monitoring Progression and Early Detection in ALS Patients	NOT_YET_RECRUITING
Small and Steatotic Hepatocellular Carcinoma	Cancer	À vérifier	NCT03428321	Small and Steatotic Hepatocellular Carcinoma	COMPLETED
Telangiectatic Palmoplantar Keratoderma in Systemic and Subacute Lupus Erythematosus	Lupus	À vérifier	NCT04356014	Telangiectatic Palmoplantar Keratoderma in Systemic and Subacute Lupus Erythematosus	UNKNOWN
Influence of Sodium Intake on Left Ventricular-arterial Coupling	Hypertension	NA	NCT01965236	Influence of Sodium Intake on Left Ventricular-arterial Coupling	TERMINATED

Publications

Molécule	Titre	Journal
Blood test	Immature platelet fraction as a prognostic marker in patients with pulmonary embolism.	Platelets
Blood test	Agouti signalling protein and triglyceride-glucose index in early pregnancy with gestational diabetes: a prospective cohort study.	Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
Blood test	Present status of prostate cancer diagnosis, limitations, challenges, and future endeavors.	Annals of medicine
UNZUELUZON ALS — Developing a Comprehensive Biomarker Panel for Monitoring Progression and Early Detection in ALS Patients	[Advances in the Structure and Function of Neurofilament Protein and Its Application in Early Diagnosis of Amyotrophic Lateral Sclerosis].	Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
Small and Steatotic Hepatocellular Carcinoma	Risk of HCC in Elderly Patients With MASLD: Proposal of an Effective Surveillance Strategy.	Journal of gastroenterology and hepatology
Small and Steatotic Hepatocellular Carcinoma	Targeting cancer stem cells enhances multikinase inhibitor therapy in metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma.	Gut
Small and Steatotic Hepatocellular Carcinoma	Fluorescence imaging for liver diseases: probe design strategies and diagnostic applications.	Nanoscale